about
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.How is patient care for multiple myeloma advancing?Emerging antibodies for the treatment of multiple myeloma.The Challenges of Daratumumab in Transfusion Medicine.Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaNew Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
P2860
Q36363958-5E995BC9-28CE-44FE-8E9D-CBDD917AD842Q37076421-9E89B86D-2C71-424A-95DD-1B18B7B9F4DAQ38786149-B136374B-31C6-44BC-85FA-7CC07005801BQ38838239-ECB8D143-40D4-405E-84CD-00F778602587Q38994343-1A0F489D-833E-4CD4-A775-E507103477D0Q39146499-1AE0C989-7B12-4689-830D-EA776756EF7CQ39417506-769032D5-B16F-4980-9DAD-BAD64349FC5BQ42046550-7C2728C9-530D-40FF-A7E2-2680B8EEE2F5Q47221234-185B2FAF-196C-4811-ABFD-9AA71B0651D2Q47307445-1009600F-F73F-4608-B830-2BD312D698DBQ47344786-D74BE7F3-4C68-4069-9BDE-BCA610BDE9DFQ47688664-6D263887-B232-4DD6-B926-1C5D1C3CEB62Q50061670-DC136DD5-1400-420D-9C4E-86C024177254Q58099961-443FE555-6997-4911-86BA-D895B2CC6776
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Daratumumab: First Global Approval.
@ast
Daratumumab: First Global Approval.
@en
Daratumumab: First Global Approval.
@nl
type
label
Daratumumab: First Global Approval.
@ast
Daratumumab: First Global Approval.
@en
Daratumumab: First Global Approval.
@nl
prefLabel
Daratumumab: First Global Approval.
@ast
Daratumumab: First Global Approval.
@en
Daratumumab: First Global Approval.
@nl
P2860
P1433
P1476
Daratumumab: First Global Approval.
@en
P2093
Kate McKeage
P2860
P2888
P304
P356
10.1007/S40265-015-0536-1
P577
2016-01-04T00:00:00Z
P6179
1018849093